GEN Exclusives

More »

GEN News Highlights

More »
Feb 7, 2012

Pieris Receives €1M BMBF Grant to Support Development of c-Met Inhibitor

  • Pieris received a €1 million grant from the German Federal Ministry of Education and Research (BMBF) to support further development of its preclinical-stage anticancer c-Met inhibitor PRS-110. The funded research will focus on defining a biomarker strategy for use alongside early clinical development, and to help define patient populations who may be suitable for treatment with the drug.

    PR-110 has completed in vivo proof-of-concept trials in preclinical models. “We believe we have developed a best in class drug candidate that rivals other advanced targeted therapies addressing the c-Met pathway based on PRS-100’s monovalent mode of target engagement,” comments Stephen Yoder, Pieris CEO.

    The firm is developing a pipeline of drugs based on its anticalin protein technology, for diseases including cancer, asthma, and autoimmune-related disorders. Lead anti-VEGF anticalin candidate PRS-050 is in development for the treatment of cancer, and completed its first clinical trial in the latter half of 2011. Also last year, Pieris and a consortium of collaborators received €6 million from the EU’s Framework Seven Program to support development of the firm’s anti-hepcidin candidate PRS-080 for treating multiple types of anemia. The Pieris-led Eurocalin consortium will take PRS-080 through to completion of a Phase Ib clinical trial. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?